Stoke Therapeutics (STOK) Net Income Growth (1y) (2019 - 2026)
Stoke Therapeutics (STOK) Net Income Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | -0.46% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 63.48% |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 1,228.66% |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - | -144.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -144.30% |
| Dec 31, 2025 | -323.50% |
| Sep 30, 2025 | -45.09% |
| Jun 30, 2025 | 8.61% |
| Mar 31, 2025 | 527.99% |
| Dec 31, 2024 | 90.94% |
| Sep 30, 2024 | 2.74% |
| Jun 30, 2024 | 30.73% |
| Mar 31, 2024 | -6.73% |
| Dec 31, 2023 | -30.69% |
| Sep 30, 2023 | 7.19% |
| Jun 30, 2023 | -15.24% |
| Mar 31, 2023 | 4.94% |
| Dec 31, 2022 | -38.92% |
| Sep 30, 2022 | -15.86% |
| Jun 30, 2022 | -42.52% |
| Mar 31, 2022 | -54.46% |
| Dec 31, 2021 | -516.77% |
| Sep 30, 2021 | -83.68% |
| Jun 30, 2021 | -53.40% |